Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism

Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.

Abstract

Hyperprogression (HP) is a recently defined clinical phenomenon in which patients treated with immunotherapy paradoxically exhibit rapid tumor growth. The mechanisms of hyperprogression remain ill-defined, although recent studies in this issue point to a possible role for Fc receptors in this process.See related article by Lo Russo et al., p. 989.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Immunotherapy
  • Lung Neoplasms*
  • Macrophages
  • Programmed Cell Death 1 Receptor
  • Receptors, Fc

Substances

  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor
  • Receptors, Fc